AI Summary

GLP‑1 weight‑loss drugs are hailed as one of the biggest biotech breakthroughs of the past decade, but some clinical psychologists warn they may also trigger eating disorders. A new report finds that the global incidence of anorexia nervosa and bulimia nervosa increased dramatically, rising 71 % between 1990 and 2023. The findings suggest a possible link between the popularity of GLP‑1 medications and the surge in these disorders.

AI summaries can be wrong sometimes—always verify important details using the source article.